Sukhi Jagpal - Jul 1, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Signature
/s/ Mary Christina Thomson, Attorney-In-Fact for Sukhi Jagpal
Stock symbol
SRRA
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/1/2022, 04:42 PM
Previous filing
Jun 17, 2022
Next filing
Aug 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -3.86K -100% $0.00* 0 Jul 1, 2022 Common Stock 3.86K $122.20 Direct F1, F2
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -1.22K -100% $0.00* 0 Jul 1, 2022 Common Stock 1.22K $263.20 Direct F2, F3
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -4.2K -100% $0.00* 0 Jul 1, 2022 Common Stock 4.2K $72.80 Direct F2, F4
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -1.75K -100% $0.00* 0 Jul 1, 2022 Common Stock 1.75K $58.00 Direct F2, F5
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -4.51K -100% $0.00* 0 Jul 1, 2022 Common Stock 4.51K $94.40 Direct F2, F6
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -5K -100% $0.00* 0 Jul 1, 2022 Common Stock 5K $78.40 Direct F2, F7
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -94.1K -100% $0.00* 0 Jul 1, 2022 Common Stock 94.1K $13.31 Direct F8, F9
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -49K -100% $0.00* 0 Jul 1, 2022 Common Stock 49K $12.15 Direct F9, F10
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -5.89K -100% $0.00* 0 Jul 1, 2022 Common Stock 5.89K $12.15 Direct F9, F11
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -30K -100% $0.00* 0 Jul 1, 2022 Common Stock 30K $16.73 Direct F9, F12
transaction SRRA Stock Option (right to buy) Disposed to Issuer $0 -50K -100% $0.00* 0 Jul 1, 2022 Common Stock 50K $31.54 Direct F9, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sukhi Jagpal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option fully vested on February 2, 2019.
F2 Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
F3 The option fully vested on January 1, 2020.
F4 The option fully vested on September 30, 2019.
F5 The option fully vested on January 1, 2021.
F6 The option fully vested on January 1, 2022.
F7 The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
F8 The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9 Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F10 On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
F11 The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F12 The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
F13 The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.